List view / Grid view
When reviewing the range of activities required to deliver pharmaceutical products of the required high quality within a strict regulatory framework, an organisation will identify services, which while still business critical, are considered as non-core to the mission of the organisation. These non-core services still need to be delivered, either…
In this issue: Miniaturisation of freeze drying equipment, driving excellence in premises and equipment management, a guide to ingredients, and much more...
Corporate codes of ethics can have reverse effects and mask anomalies or social evils in operations outsourced to low-wage countries...
Antalis’ customers are set to benefit from a fleet of more technologically advanced vehicles as part of its £5m partnership with fleet provider, Fraikin...
Patheon’s Joe Principe examines current trends in outsourcing, highlighting the importance of investment in CDMO partnerships...
Thermo Fisher Scientific announced yesterday that it would buy contract development and manufacturing organisation (CDMO) Patheon for $7.2bn...
4 April 2017 | By Christoph Huwe, Strategic Alliance Manager Therapeutics at Bayer Pharmaceuticals, Global External Innovation & Alliances
Ahead of the 7th Annual Strategic Alliance Management for Pharma conference, we spoke with Bayer's Christoph Huwe about the organisational development of alliance management...
Dr. Timothy S. Oostdyk, Group Senior Vice President of Eurofins BioPharma Product Testing, discusses the issues affecting outsourcing to the biopharmaceutical industry and the benefits of having a wide global reach...
15 October 2015 | By Victoria White
CPhI highlights these risks in the fourth and final section of its 2015 annual report, The Outsourcing perspective...
Batavia Bioservices has changed its name to Batavia Biosciences as of 23 April 2015. The change will coincide with the launch of a new website and multimedia communication strategy.
20 April 2015 | By Roger A. Stroud, R Stroud Pharmaceutical Quality Solutions Limited
Increasing numbers of pharmaceutical companies are considering outsourcing in the area of analytical and microbiological testing, from the very smallest start-up, virtual, or small company up to the largest multinational. This article will examine the factors that lead to a company deciding to outsource, and provides invaluable guidance on the…
23 December 2014 | By Eurofins BioPharma
The largest network of harmonised bio/pharmaceutical gross manufacturing product (GMP) testing laboratories worldwide, Eurofins BioPharma Product Testing enables companies to advance candidates from development through to commercialisation while ensuring regulatory compliance, cost effectiveness and achievement of timelines...
Leader in contract bio/pharma industry intelligence predicts ongoing in-house manufacture...
15 April 2014 | By European Pharmaceutical Review
Timothy S. Oostdyk, PhD, President of Eurofins Lancaster Laboratories; Sr. Vice President, Eurofins BioPharma Product Testing Group, discusses harmonising policies, quality and services among 14 global facilities.
19 February 2014 | By Allen L. Burgenson, Manager - Regulatory Affairs, Lonza Walkersville, Inc
Allen L. Burgenson, Manager - Regulatory Affairs, Lonza Walkersville, Inc answers the question “From a vendor perspective, do you conclude that Big Pharma is still actively engaging in outsourcing of the activities that you have expertise in?”
